Crititech, Inc.

Joseph S Farthing

Michael Baltezor

Mark D Williams

Matthew McClorey

Jahna Espinosa

Jacob M Sittenauer

Samuel Campbell

Julia K Fischer

Jake Sittenauer

Gary E Clapp

Shelby Clark

Gere Dizerega

Aranza Barreda Abarca

Bala Subramaniam

Greg Johnson

Gregory F Johnson

Matthew Mcclorey

Garry E Clapp

The disclosure provides particles of at least 95% by weight of lapatinib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 10 m/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm.

Lapatinib particles and uses thereof

Disclosed herein are particles of at least 95% by weight of a glucocorticoid that have a specific surface area of at least 10 mmethods for making, such particles, and methods for their use as therapeutics. Also disclosed herein are particles of at least 95% by weight of an indolinone that have a specific surface area of at least 10 m/g, methods for making such particles, and methods for-their use as therapeutics.

Glucocorticoid 'nintedanib' particles and their use

Compositions of particles having at least 95% by weight of niraparib and a specific surface area (SSA) of at least 5 m/g, methods for their use, and methods for their production are provided.

Niraparib particles and uses thereof

Compositions of particles having at least 95% by weight of rucaparib and a specific surface area (SSA) of at least 12 m/g, methods for their use, and methods for their production are provided.

Rucaparib particles and uses thereof

The present disclosure provides an apparatus and methods of use for isolating particles. An example apparatus includes (a) a vessel defining a pressurizable chamber, wherein the vessel includes a distal end and a proximal end, (b) an inlet of the pressurizable chamber at the proximal end of the vessel, (c) a nozzle positioned within the pressurizable chamber, wherein the nozzle includes an inlet tube in fluid communication with the inlet of the pressurizable chamber, wherein the nozzle includes an outlet aperture, wherein the nozzle is adjustable to alter a distance between the proximal end of the vessel and the outlet aperture of the nozzle, and wherein the nozzle is adjustable to alter an angle between a longitudinal axis of the vessel and a longitudinal axis of the nozzle, and (d) an outlet of the pressurizable chamber at the distal end of the vessel.

Nozzle assembly and methods for use

Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cmand about 0.15 g/cm, and/or a specific surface area (SSA) of at least 18 m/g, 20 m/g, 25 m/g, 30 m/g, 32 m/g, 34 m/g, or 35 m/g. Methods for making and using such compositions are also provided.

Taxane particles and their use

The present disclosure relates to ciprofloxacin polymorphs and their use in treating infections.

Ciprofloxacin polymorph and its use

The present disclosure provides an apparatus and methods of use for collecting particles. An example collection device includes (a) a vessel defining a chamber, wherein the vessel includes a distal end and a proximal end, (b) an inlet port extending from the proximal end of the vessel, wherein the inlet port is in fluid communication with the chamber, and (c) an outlet port extending from the proximal end of the vessel, wherein the inlet port is in fluid communication with the chamber, and wherein the outlet port includes a porous material positioned between the chamber and the outlet port.

Growing community of inventors

Lawrence, KS, United States of America

Joseph S Farthing